Please ensure Javascript is enabled for purposes of website accessibility

Facebook's Head of Health: "Misinformation Really Thrives In the Absence of Credible Information"

By Corinne Cardina - Feb 28, 2021 at 7:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

KX Jin explains Facebook's strategy of promoting accurate information about the pandemic and removing debunked health claims.

With more than 2.6 billion daily users, it's no secret that Facebook (META -0.76%) reaches a lot of people around the world across Facebook, Messenger, Instagram, and WhatsApp. Building on its COVID-19 information center, the tech stock recently announced a big push to provide authoritative information about coronavirus vaccines. This new campaign will connect users with localized vaccine information, remove more vaccine misinformation from its platforms, and donate $120 million in ad credits to health agencies. 

Corinne Cardina,'s healthcare and cannabis bureau chief, got the chance to speak with KX Jin, Facebook's Head of Health, on Feb. 10 about Facebook's plan to increase trust in COVID vaccines. He talked about the company's commitment to providing accurate information on vaccines and removing posts that contain false information.



Corinne Cardina: Facebook announced as part of this campaign that it is expanding efforts to remove false claims on Facebook and Instagram about COVID-19 as well as vaccines. The press release said, since the pandemic began, the company has removed more than 12 million pieces of content on Facebook and Instagram containing misinformation that could lead to eminent physical harm. Could you elaborate on the expanding efforts pertaining to the vaccine part?

KX Jin: Misinformation really thrives in the absence of credible information. Ultimately, what everyone wants is to keep themselves safe and healthy, and to keep their loved ones safe and healthy. That's why we've been so focused on a lot of the efforts to help people get credible information on our platform that I talked about today. As I mentioned, a lot of these things I think had real positive impacts and have been quite effective. At the same time, it's also important that we work on misinformation. We've been doing this, honestly, since the day the WHO declared this thing to be a public health emergency. We've been removing false claims around COVID-19 that could cause harm to folks that have been debunked by public health authorities. We've been updating that policy as the pandemic evolved and as our understanding or the world's understanding of things have changed. Early on, guidance around masks was much more mixed, and as the guidance around masks became clear, we've updated our policies in response. The announcement today on the misinformation side, I would view as an extension of our approach here. A year in, tremendously grateful that we have vaccines that work, and we want to make sure that we're removing misinformation along those lines as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$160.03 (-0.76%) $-1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.